A PHASE 1, RANDOMIZED, OPEN-LABEL, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE EFFECT OF PF-06865571 ON THE PHARMACOKINETICS OF METFORMIN IN HEALTHY ADULT SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs PF 06865571 (Primary) ; Metformin
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Jan 2019 Planned End Date changed from 12 Feb 2019 to 13 Feb 2019.
- 14 Dec 2018 Status changed from suspended to recruiting.
- 07 Dec 2018 Planned End Date changed from 12 Mar 2019 to 12 Feb 2019.